

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

November 2012

Vol. 40, No. 11

CONTENTS

SHORT COMMUNICATION

- Characterization of THLE-Cytochrome P450 (P450) Cell Lines: Gene Expression Background and Relationship to P450-Enzyme Activity. *Yalda Soltanpour, Constanze Hilgendorf, Marie M. Ahlström, Alison J. Foster, J. Gerry Kenna, Anne Petersen, and Anna-Lena Ungell* **2054**

ARTICLES

- Vitamin D Receptor Activation Enhances Benzo[a]pyrene Metabolism via CYP1A1 Expression in Macrophages. *Manabu Matsunawa, Daisuke Akagi, Shigeyuki Uno, Kaori Endo-Umeda, Sachiko Yamada, Kazumasa Ikeda, and Makoto Makishima* **2059**

- Pharmacokinetics of Oral D-Serine in D-Amino Acid Oxidase Knockout Mice. *Rana Rais, Ajit G. Thomas, Krystyna Wozniak, Ying Wu, Hanna Jaaro-Peled, Akira Sawa, Christine A. Strick, Sandra J. Engle, Nicholas J. Brandon, Camilo Rojas, Barbara S. Slusher, and Takashi Tsukamoto* **2067**

- Oxidative ipso Substitution of 2,4-Difluoro-benzylphthalazines: Identification of a Rare Stable Quinone Methide and Subsequent GSH Conjugate. *Mithat Gunduz, Upendra A. Argikar, Amin Kamel, Kevin Colizza, Jennifer L. Bushee, Amanda Cirello, Franco Lombardo, and Shawn Harriman* **2074**

- ATP Serves as an Endogenous Inhibitor of UDP-Glucuronosyltransferase (UGT): A New Insight into the Latency of UGT. *Yuji Ishii, Kie An, Yoshio Nishimura, and Hideyuki Yamada* **2081**

- Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies. *James F. Sigafos, Gary D. Bowers, Stephen Castellino, Amanda G. Culp, David S. Wagner, Melinda J. Reese, Joan E. Humphreys, Elizabeth K. Hussey, Robin L.*

- O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L. Dobbins, and Joseph W. Polli* **2090**

- The Role of a Basolateral Transporter in Rosuvastatin Transport and Its Interplay with Apical Breast Cancer Resistance Protein in Polarized Cell Monolayer Systems. *Jibin Li, Ying Wang, Wei Zhang, Yuehua Huang, Kristin Hein, and Ismael J. Hidalgo* **2102**

- Metabolism and Pharmacokinetics of Mangiferin in Conventional Rats, Pseudo-Germ-Free Rats, and Streptozotocin-Induced Diabetic Rats. *Huihui Liu, Bin Wu, Guoyu Pan, Lei He, Zhixiong Li, Mingsong Fan, Longhai Jian, Mingcang Chen, Ke Wang, and Chenggang Huang* **2109**

- Cytochrome P450 2S1 Depletion Enhances Cell Proliferation and Migration in Bronchial Epithelial Cells, in Part, through Modulation of Prostaglandin E₂ Synthesis. *T. W. Madanayake, T. P. Fidler, T. M. Fresquez, N. Bajaj, and A. M. Rowland* **2119**

- Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats. *Abdulaziz M. S. Alsaad, Beshay N. M. Zordoky, Ahmed A. El-Sherbeni, and Ayman O. S. El-Kadi* **2126**

- Impact of Organic Solvents on Cytochrome P450 Probe Reactions: Filling the Gap with (S)-Warfarin and Midazolam Hydroxylation. *Vanessa González-Pérez, Elizabeth A. Connolly, Arlene S. Bridges, Larry C. Wienkers, and Mary F. Paine* **2136**

- Metabolism, Excretion, and Pharmacokinetics of ((3,3-Difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human. *Raman Sharma, Hao Sun, David W. Piotrowski, Tim F. Ryder, Shawn D. Doran, Haiqing Dai, and Chandra Prakash* **2143**

- An Evaluation of Using Rat-Derived Single-Dose Neuropharmacokinetic Parameters to Project Accurately Large Animal Unbound Brain Drug

Continued on next page

- Concentrations. *Angela C. Doran, Sarah M. Osgood, Jessica Y. Mancuso, and Christopher L. Shaffer* **2162**
- [S] Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands. *Krishna C. Chimalakonda, Kathryn A. Seely, Stacie M. Bratton, Lisa K. Brents, Cindy L. Moran, Gregory W. Endres, Laura P. James, Paul F. Hollenberg, Paul L. Prather, Anna Radominska-Pandya, and Jeffery H. Moran* **2174**
- [S] Novel Bioactivation Mechanism of Reactive Metabolite Formation from Phenyl Methyl-Isoxazoles. *Johan Bylund, Istvan Macsari, Yevgeni Besidski, Susanne Olofsson, Carl Petersson, Per I. Arvidsson, and Tjerk Bueters* **2185**
- UDP-Glucuronic Acid Binds First and the Aglycone Substrate Binds Second to Form a Ternary Complex in UGT1A9-Catalyzed Reactions, in Both the Presence and Absence of Bovine Serum Albumin. *Nenad Manevski, Jari Yli-Kauhaluoma, and Moshe Finel* **2192**
- [S] Utility of DPX2 Cells for Predicting CYP3A Induction-Mediated Drug-Drug Interactions and Associated Structure-Activity Relationships. *Odette A. Fahmi, Judy L. Raucy, Elsa Ponce, Saleema Hasanali, and Jerome M. Lasker* **2204**
- [S] Generation and Characterization of a Novel Multi-drug Resistance Protein 2 Humanized Mouse Line. *Nico Scheer, Praveen Balimane, Michael D. Hayward, Sandra Buechel, Gunther Kauselmann, and C. Roland Wolf* **2212**

LETTERS TO THE EDITOR

- Reevaluation of the Roles of ABCG2 in the Disposition of Genistein. *Ana I. Álvarez, Fernando Vallejo, Borja Barrera, Gracia Merino, Julio G. Prieto, Francisco Tomás-Barberán, and Juan C. Espín* **2219**
- Response to Letter to the Editor on “Breast Cancer Resistance Protein (ABCG2) Determines Distribution of Genistein Phase II Metabolites: Reevaluation of the Roles of ABCG2 in the Disposition of Genistein.” *Zhen Yang, Wei Zhu, Song Gao, Taijun Yin, Wen Jiang, and Ming Hu* **2219**

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Molecular docking of PF-00734200 in CYP2D6 pose 1 (A) and pose 2 (B) and in CYP3A4 pose 1 (C) and pose 2 (D) active sites. See the article by Sharma et al. on page 2143 of this issue.